It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Host lipid metabolism and viral responses are intimately connected. However, the process by which the acquired immune systems adapts lipid metabolism to meet demands, and whether or not the metabolic rewiring confers a selective advantage to host immunity, remains unclear. Here we show that viral infection attenuates the expression of genes related to lipid metabolism in murine CD4+ T cells, which in turn increases the expression of antiviral genes. Inhibition of the fatty acid synthesis pathway substantially increases the basal expression of antiviral genes via the spontaneous production of type I interferon (IFN). Using a combination of CRISPR/Cas9-mediated genome editing technology and a global lipidomics analysis, we found that the decrease in monounsaturated fatty acid caused by genetic deletion of Scd2 in mice was crucial for the induction of an antiviral response through activation of the cGAS-STING pathway. These findings demonstrate the important relationship between fatty acid biosynthesis and type I IFN responses that enhances the antiviral response.
Kanno et al. demonstrate that decreased monounsaturated fatty acid in CD4 + T cells following Scd2 deletion boosts the induction of the antiviral response via activation of the cGAS-STING pathway in mice. This study highlights the important interaction between fatty acid metabolism and the acquired immune response.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Kazusa DNA Research Institute, Department of Frontier Research and Development, Laboratory of Medical Omics Research, Kisarazu, Japan (GRID:grid.410858.0) (ISNI:0000 0000 9824 2470)
2 The Jikei University School of Medicine, Department of Bacteriology, Tokyo, Japan (GRID:grid.411898.d) (ISNI:0000 0001 0661 2073); The Jikei University School of Medicine, Jikei Center for Biofilm Science and Technology, Tokyo, Japan (GRID:grid.411898.d) (ISNI:0000 0001 0661 2073)
3 Gene Expression Laboratory (GEL-B) Salk Institute for Biological Studies, La Jolla, USA (GRID:grid.250671.7) (ISNI:0000 0001 0662 7144); Chiba University, Department of Regenerative Medicine, School of Medicine, Chuo-ku, Japan (GRID:grid.136304.3) (ISNI:0000 0004 0370 1101)
4 National Institute of Infectious Disease, Department of Immunology, Shinjuku-ku, Japan (GRID:grid.410795.e) (ISNI:0000 0001 2220 1880)
5 Department of Applied Genomics Kazusa DNA Research Institute, Kisarazu, Japan (GRID:grid.410858.0) (ISNI:0000 0000 9824 2470)
6 Chiba University, Department of Immunology, Graduate School of Medicine, Chuo-ku, Japan (GRID:grid.136304.3) (ISNI:0000 0004 0370 1101); AMED-CREST, AMED, Chuo-ku, Japan (GRID:grid.480536.c) (ISNI:0000 0004 5373 4593)
7 Kazusa DNA Research Institute, Department of Frontier Research and Development, Laboratory of Medical Omics Research, Kisarazu, Japan (GRID:grid.410858.0) (ISNI:0000 0000 9824 2470); Chiba University, Department of Omics Medicine, Graduate School of Medicine, Chuo-ku, Japan (GRID:grid.136304.3) (ISNI:0000 0004 0370 1101)